• RankiaPro Europe
    • RankiaPro Spain
    • RankiaPro LATAM
    • RankiaPro Italy
SUBSCRIBE
Search
Close
  • Home
  • Insights
    EQUITIES
    EQUITIES
    FIXED INCOME
    FIXED INCOME
    ESG
    ESG
    INTERVIEWS
    INTERVIEWS
    MARKET OUTLOOK
    MARKET OUTLOOK
    ETF
    ETF

    Featured

    Cover-Silicon-Valley-Bank-bankruptcy
    Insights

    Silicon Valley Bank bankruptcy: the market reactions

  • News
    APPOINTMENTS
    APPOINTMENTS
    LAUNCHES
    LAUNCHES
    ASSET MANAGERS
    ASSET MANAGERS

    FEATURED

    cover-naim-abou-jaoude-ceo-candriam
    Asset Managers

    Candriam to acquire majority shareholding in Tristan Capital Partners: a leading european real estate manager

  • Magazine
  • Events
    RANKIA FUNDS EXPERIENCE
    EVENTS & CONFERENCE CALLS
    EVENTS & CONFERENCE CALLS
    RANKIAPRO MEETINGS
    RANKIAPRO MEETINGS
  • Podcast
  • MiFIDII Training
Menu
  • Home
  • Insights
    EQUITIES
    EQUITIES
    FIXED INCOME
    FIXED INCOME
    ESG
    ESG
    INTERVIEWS
    INTERVIEWS
    MARKET OUTLOOK
    MARKET OUTLOOK
    ETF
    ETF

    Featured

    Cover-Silicon-Valley-Bank-bankruptcy
    Insights

    Silicon Valley Bank bankruptcy: the market reactions

  • News
    APPOINTMENTS
    APPOINTMENTS
    LAUNCHES
    LAUNCHES
    ASSET MANAGERS
    ASSET MANAGERS

    FEATURED

    cover-naim-abou-jaoude-ceo-candriam
    Asset Managers

    Candriam to acquire majority shareholding in Tristan Capital Partners: a leading european real estate manager

  • Magazine
  • Events
    RANKIA FUNDS EXPERIENCE
    EVENTS & CONFERENCE CALLS
    EVENTS & CONFERENCE CALLS
    RANKIAPRO MEETINGS
    RANKIAPRO MEETINGS
  • Podcast
  • MiFIDII Training
Search
Close
Search
Close

Home | Personalised cancer vaccine, making progress against the disease

Personalised cancer vaccine, making progress against the disease

The personalized cancer vaccine should be seen as a booster aiming at meeting two objectives for cancer patients.
RankiaPro Europe

2023/01/02

By Brice Prunas, gestor de Inteligencia Artificial en Oddo BHF AM

To this day, the most widely used and effective treatment for cancer (especially for solid tumors) is a form of immunotherapy called PD1 – also known as immune checkpoint inhibitor. The best-selling drug in this category is Keytruda from Merck US. While 75% of patients are cured after one year of this treatment, there is a possible risk of recurrence.

The personalized cancer vaccine (or PCV) should be seen as a booster aiming at meeting two objectives for cancer patients: a) to increase the cure rate (or pause in the progression of the disease) from 75% to a higher rate (beyond 80%); b) to allow the monitoring of the patient’s immune system and to prevent a resurgence of their cancer.

Where are we in the development of this vaccine?

Moderna’s PCV is currently in Phase 2 of development and data should be released in the fourth quarter of 2022.

Merck US, the world leader in cancer treatment, which has had access to data from Moderna’s open-label Phase 2 study, has decided to invest $250m in Moderna. The investment which aims to co-develop and co-commercialize the PCV gives a considerable positive signal about the vaccine’s chances of success. The American oncology giant also has an economic interest in the success of Moderna’s vaccine. Indeed, the success of the vaccine would enhance and extend the efficacy of its PD1 therapy which generates tens of billions in sales each year.

It is critical to understand that the Moderna study is being conducted in an “adjuvant setting” (i.e., only in cases where the tumor has already been surgically removed) which is a factor that greatly increases the chances of success of the Moderna study. The future will tell whether such a vaccine will be successful in a “metastatic setting” – this will be more difficult, but there is hope once we understand the essence of the messenger RNA method. Finally, this personalized vaccine should offer an even greater positive outcome in cases of melanoma compared to other solid tumor cancers.

How is the combination of Messenger RNA (MRNA) and artificial intelligence pushing the boundaries of science?

Until now, it was very difficult to identify tumor markers (i.e., proteins that are produced by the cancerous tissue itself or sometimes by the body in response to the progression of the cancer) because they were undetectable by the immune system. Therefore, the effectiveness of PD1 (a form of immunotherapy) hit its glass ceiling, making any progress in the fight against cancer quite complicated.

In response to this obstacle, Moderna’s innovative approach is to:

  1. Take a sample of each patient’s tumor.
  2. Sequence it.
  3. Use elaborate algorithms to detect each patient’s unique tumor mutation.
  4. Then use Messenger RNA to label these mutant sequences (there are reportedly 34 in total)
  5. Reintroduce the Messenger RNA into the cancerous tumor to generate this protein that will mark the tumor. In this way, the tumor markers become visible to the immune system and PD1 antibodies can more effectively kill the cancer cells. The benefits of this approach would be to get rid of tumors quickly and permanently, leading to a more permanent cure of patients.
  • Cancer, impact investment, Vaccines

Related Post

COVER-coser

Modern slavery and Just Transition to zero emissions top InterAction’s themes for 2023

cover-RankiaPro-investment-funds-cancer-oncology

Funds investing in the fight against cancer: investing in oncology companies

Cover-metals-SycomoreAM-RankiaPro

How should investors be positioned on energy transition metals?

NEWSLETTER
If you want to keep up to date with the latest news from the asset management industry and all our events, subscribe now to our newsletter.
Subscribe

Last Tweets

10h

🌤 The crucial role of resources in the energy transition debate

🔗#EnergyTransition #Resources #RankiaProEurope
...https://rankiapro.com/en/crucial-role-resources-energy-transition-debate/

10h

🗣️Change to @Amundi_ENG corporate governance

🔗 #Appoinment #Change #RankiaProEurope
...https://rankiapro.com/en/change-to-amundis-corporate-governance/

13h

🎙We introduce you to the new #AdvisoroftheMonth
João Martins, Senior Private Banker at ABANCA Portugal.
Don't miss
... his interview!

🔗#ProfessionaloftheMonth #RankiaProEurope
https://rankiapro.com/en/joao-martins-abanca-portugal-our-advisor-month/

14 Mar

🗣️ @Robeco launches Sustainable Senior Loan Fund

🔗#PrivateDebt #Sustainability #RankiaProEurope
...https://rankiapro.com/en/robeco-launches-sustainable-senior-loan-fund/

RankiaPro

  • Home
  • Insights
  • News
  • Magazine
  • Events
  • About us
Menu
  • Home
  • Insights
  • News
  • Magazine
  • Events
  • About us

Terms and uses

  • Cookies Policy
  • Privacy Policy
  • Disclaimer
Menu
  • Cookies Policy
  • Privacy Policy
  • Disclaimer

Contact

  • [email protected]
  • (+34) 963 386 976
  • (+34) 640 308 023

Newsletter

If you want to keep up to date with the latest news from the asset management industry and all our events, subscribe now.

Subscribe

All rights reserved © 2003 – 2023 Rankia S.L.

RankiaPro

  • Home
  • Insights
  • News
  • Magazine
  • Events
  • About us
Menu
  • Home
  • Insights
  • News
  • Magazine
  • Events
  • About us

Terms and uses

  • Cookies Policy
  • Privacy Policy
  • Disclaimer
Menu
  • Cookies Policy
  • Privacy Policy
  • Disclaimer

Contact

  • Email: [email protected]
  • Phone: 963 386 976 – 601 302 692

All rights reserved © 2003 – 2023 Rankia S.L.

Manage Cookie Consent
To provide you the best experience on our website, we use technologies like our own and third-party cookies for analytical purposes and to store device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique identifiers on this site. Not consenting or withdrawing consent may adversely affect certain features and functions.

To learn more, please read our Cookie Policy and Privacy Statement.
Functionality or Personalisation Cookies Always active
These cookies are necessary for the website to function or for the unique purpose of transmitting a communication over an electronic communications network, and cannot be disabled on our systems. Usually they are set up to respond to actions made by you to receive services, such as adjusting your privacy preferences or filling out forms. You can set your browser to block or alert you to the presence of these cookies, but some parts of the website will not work. These cookies allow the website to provide better functionality and personalisation. They may be set by us or by third parties whose services we have added to our pages. If you do not allow these cookies some of our services will not work properly.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics Cookies
These cookies allow us to count traffic sources in order to measure and improve the performance of our website. Storage or technical access which is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing Cookies
These cookies may be site-wide, placed by our advertising partners. These third parties may use them to create a profile of your interests and show you relevant adverts on other sites. If you do not allow these cookies, you may receive less targeted advertising.
Manage options Manage services Manage vendors Read more about these purposes
Cookie Settings
{title} {title} {title}
  • RankiaPro Europe
    • RankiaPro Spain
    • RankiaPro LATAM
    • RankiaPro Italy
Menu
  • Home
  • Insights
    • Equities
    • ESG
    • ETF
    • Fixed Income
    • Interviews
    • Market Outlook
  • News
    • Appointments
    • Asset Managers
    • Launches
  • Magazine
  • Events
    • Events & Conference calls
    • Rankia Funds Experience
    • RankiaPro Meetings
  • Podcast
  • MIFIDII Training

Follow us on social media

Linkedin Twitter Youtube Flickr

NEWSLETTER

Subscribe

Book now

Personalised cancer vaccine, making progress against the disease